Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR10900578

1825be7d-2aa3-50c0-b2c0-6b7242a23981

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.500
  • OXIDATIVE_PHOSPHORYLATION+0.500
  • MYC_TARGETS_V1+0.400
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • DNA_REPAIR+0.200
  • ADIPOGENESIS+0.100
  • ANDROGEN_RESPONSE+0.100
  • ESTROGEN_RESPONSE_LATE+0.100
  • FATTY_ACID_METABOLISM+0.100
  • ESTROGEN_RESPONSE_EARLY+0.000

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
  • ANGIOGENESIS-0.500
  • COAGULATION-0.400
  • COMPLEMENT-0.400
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INFLAMMATORY_RESPONSE-0.400
  • MITOTIC_SPINDLE-0.400
  • NOTCH_SIGNALING-0.400
  • TGF_BETA_SIGNALING-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518209
breast-umap@18
C0.904
2SRR1313095
breast-umap@18
B0.894
320110028.LumB
breast-umap@18
B0.880
4R16
bladder-landscape@3
0.879
520070010.LumB
breast-umap@18
B0.865
6SRR1316874
brain-umap@2
GTEX0.862
7SRR5088853
melanoma-umap@29
0.862
8SRR1364893
brain-umap@2
GTEX0.859
9SRR1313092
breast-umap@18
B0.854
10TCGA-5T-A9QA-01A-11R-A41B-07
breast-umap@18
B0.854

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 9 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.500Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.500Remibrutinib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
DNA_REPAIR0.200Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered